



## Swedish Society for Virology (SSV) Newsletter, November 2024

### 1) **Nominations for Awards:**

- The board welcomes nominations of candidates to the **Pandemifonden Awards, The Sigvards Olofsson Prize and the Pandemifonden Fenyö Prize**, which will be given by Virus- och pandemifonden – Svenska Sällskapet för Virologi, to two junior, talented virologists working at Swedish universities or hospitals, for the purpose of promoting virus research. For 2024, the award will be 100 000 SEK given to each awardee. See attached pdf for details on the eligibility of candidates and nominations, to be **submitted latest Nov 15, 2024**, to [info@pandemifonden.se](mailto:info@pandemifonden.se)

### 2) **Call for proposal:**

- Virus- och pandemifonden" – in collaboration other actors – have organized a fundraising campaign for research on virus-caused infections in children. The campaign collected 137 000 SEK. "Virus- och pandemifonden" raises another 67 000 SEK and is now announcing **A one-year research grant of 200,000 SEK for research on virus-caused infections in children**. See attached pdf for details on the grant call and instructions for the application, to be **submitted latest Nov 15, 2024**, to [info@pandemifonden.se](mailto:info@pandemifonden.se)

### 3) **Meetings:**

- **34th Annual Meeting of the German-speaking Society for Virology (GfV)**, Hamburg **March 4-7, 2025**, including plenary sessions on: Innate Immunity, Structural Virology, Virus-Host Interactions, Viral Data Science and Emerging Viruses/ Zoonoses, and many parallel workshops. For more information, registration and **Abstract deadline December 1, see [link](#). Note!** When you login for registration you should tick, under "Membership", that you are member of SSV. This since the registration fee, both for students and more senior virologists, will be reduced to the same level as for **GfV** members, as part of the aim to strengthen the cooperation between SSV and GfV.
- **9th European Congress of Virology 2025**, Dubrovnik, Croatia, **April 27-30, 2025**. For information on the program and registration see [link](#). **Abstract deadline January 5.**
- **Save the date! World Society for Virology Conference WSV2025** in Kuala Lumpur **May 6-8, 2025**. See [link](#).
- **Save the date!** Next year's **Smögen Summer Symposium on Virology** will be held **August 21-23, 2025**.

### 4) **Reports:**

Systematic overview from the **Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)** on **non-medical interventions for lowering the risk of viral transmission during pandemics** (in Swedish), see [link](#).

- 5) **Jobs:**
- **Postdoc position in Molecular Virology**, Gothenburg University. See [link](#) for more information. **Application deadline November 19.**
  - **Investigator (utredare) in laboratory surveillance of viruses and vaccines**, the Public Health Agency of Sweden (FoHM). See [link](#) for more information. **Application deadline November 28.**
  - **PhD position in Structure Biology and Virus Replication**, at Umeå University. See [link](#) for more information. **Application Deadline December 15.**
  - **Three positions as WCMF fellow (assistant senior lecturer with tenure track) in Molecular Medicine**, Umeå University. Including six-year position and a 15 million SEK package. For more information see [link](#). **Application deadline January 20.**
- 6) **Nominations of Swedish Research Council (VR) 2025 Review Panel members:**  
It is now time to nominate members of the review panels for 2025 in the Swedish Research Council's Medicine and Health panels. For instructions and submissions (**deadline November 30**) please read information in the [link](#).
- 7) **Travel Grants:**
- PhD students and postdocs are welcome to apply for **the SSV travel grants**. See how to apply on our [website](#). Applications for travel grants from SSV are now accepted during the spring term, with **deadline March 1**, and during the autumn term, with **deadline October 1**. Decisions on travel grants are then taken by the board. Each award amounts to a maximum of 10.000 SEK. If you have further questions, contact [ake.lundkvist@imbim.uu.se](mailto:ake.lundkvist@imbim.uu.se)
- 8) **Opportunities with the German Society of Virology (GfV):**
- Opportunity to join and interact with the **Young Investigators of GfV (JGfV)**, including events, virtual seminar series, and much more, see their [webpage](#)  
Upcoming virtual seminar include topics on
- Thus, events organized by JGfV include:
- Virology Lecture Series
  - Online Education circle of the working group: clinical virology
  - How to... Methods lecture series
  - Additional workshops (partly in german)
  - Online "discussion Round" format on career related topics.
- 9) **Pandemifonden activities:**  
For those of you that are active at **social media**, it would also be a great help to increase awareness – and donations – if you follow/share Pandemifondens messages. If you feel comfortable, recommend your network to follow Pandemifonden:
- Instagram: <https://www.instagram.com/pandemifonden/>
  - Facebook: <https://www.facebook.com/Pandemifonden>
  - LinkedIn: <https://www.linkedin.com/company/pandemifonden/>

- 10) **Reminder!** We kindly ask you to post, in your neighborhood, the attached Pandemifonden poster, with information on activities and how to donate money, including QR code.
- 11) [Information](#) on Virus- och Pandemifonden – **Swedish Society for Virology membership:** Attending the Smögen Summer Symposium on Virology will make you, free of charge, member of SSV for the coming three years. If you want to opt out of the membership, do not want to receive Newsletters or have **suggestions for the Newsletter or the webpage**, please contact [marianne.jansson@med.lu.se](mailto:marianne.jansson@med.lu.se)

**Greetings to all members (n=311)  
from SSV**



## Creating Possible.

**Gilead is a research-based biopharmaceutical company that discovers, develops and delivers innovative therapeutics for people with life-threatening diseases.**

At Gilead, we set and achieve bold ambitions in our fight against the world's most devastating diseases. We are driven by our purpose of making the world a healthier place for all people. That means delivering innovative therapies that offer new hope for patients. Our ambitions have led us to a cure for hepatitis C and to transforming the treatment and prevention of HIV. Our innovation is helping people with diseases and conditions that include cancer, viral hepatitis, HIV and COVID-19.

By investing in world-class science, driving access to our medicines, addressing societal barriers to care and building a culture where our employees can make a real impact, we will continue to confront the biggest public health challenges of our day for the benefit of generations to come.

Gilead Sciences Sweden AB  
Hemvärmögatan 9, 171 54 Solna  
08-505 718 00  
SE-UNB-0186

